Drug Profile
SSR 240612
Alternative Names: SSR240612Latest Information Update: 23 Mar 2009
Price :
$50
*
At a glance
- Originator sanofi-aventis
- Class Analgesics; Anti-inflammatories
- Mechanism of Action Bradykinin B1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported CNS disorders; Inflammation; Neuropathic pain; Pain
Most Recent Events
- 23 Mar 2009 No development reported - Phase-II for Pain in France (PO)
- 23 Mar 2009 No development reported - Preclinical for CNS disorders in France (PO)
- 23 Mar 2009 No development reported - Preclinical for Inflammation in France (PO)